Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT05889013 · ClinicalTrials.gov registry record
Utility of PCD Diagnostics to Improve Clinical Care
A clinical trial of Primary Ciliary Dyskinesia, sponsored by Connecticut Children's Medical Center.
- Recruiting
- Registry status
- 50
- Enrollment target
- 1
- Study location
NCT05889013: Recruiting study of Primary Ciliary Dyskinesia, sponsored by Connecticut Children's Medical Center.
NCT05889013 is a study of Primary Ciliary Dyskinesia that is actively recruiting participants, run by Connecticut Children's Medical Center. The registered enrollment target is 50 participants, below the 103-participant average among 7 other Primary Ciliary Dyskinesia trials with a reported enrollment target (51% lower). The trial reports 1 study location across 1 state. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT05889013, a study of Primary Ciliary Dyskinesia, is actively recruiting participants, sponsored by Connecticut Children's Medical Center.
- RECRUITING
- Registry status
- 50 participants
- Enrollment target
- 1
- Study location
Study Summary
This cross-sectional and longitudinal observational study is to gather data on the utility of tests that are used to make a diagnosis of primary ciliary dyskinesia (PCD). There is new testing available, called nasal nitric oxide testing, that non-invasively measures nitric oxide levels in the sinus cavity. Individuals with PCD characteristically have low levels, but this testing does not have extensive data from everyday clinical practice. The objective of this proposal is to improve the diagnostic approach to children and adults with clinical concerns for primary ciliary dyskinesia (PCD).
Primary Outcome
To establish a research registry to characterize the features of individuals that undergo PCD diagnostic testing at Connecticut Children's Medical Center and UCONN.
Conditions Studied
Interventions
- DEVICE Nasal Nitric Oxide testing
Study Locations (1)
Connecticut
- Pulmonary Division - Hartford
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 50 participants |
| Start Date | 2023-10-17 |
| Est. Completion | 2028-12 |
What NCT05889013 shows while recruiting
NCT05889013 is an observational study that tracks outcomes without assigning an intervention. The registry caps enrollment at 50 participants, a relatively small participant target, below the 103-participant average among 7 other Primary Ciliary Dyskinesia trials with a reported enrollment target (51% lower).
The record links to 1 condition, with Primary Ciliary Dyskinesia appearing as the primary indexed condition, and to 1 intervention - of which Nasal Nitric Oxide testing is the first listed.
NCT05889013 reports a single indexed study location in Connecticut.
Frequently Asked Questions
What is clinical trial NCT05889013 about?
NCT05889013 is a clinical study titled "Utility of PCD Diagnostics to Improve Clinical Care". This cross-sectional and longitudinal observational study is to gather data on the utility of tests that are used to make a diagnosis of primary ciliary dyskinesia (PCD). There is new testing available, called nasal nitric oxide testing, that non-invasively measures nitric oxide levels in the sinus ...
What is the current status of trial NCT05889013?
This trial is currently recruiting. The enrollment target is 50 participants. The study started on 2023-10-17. Estimated completion is 2028-12.
What conditions does trial NCT05889013 study?
This clinical trial studies the following conditions: Primary Ciliary Dyskinesia.
What interventions are being tested in trial NCT05889013?
The interventions under investigation include: Nasal Nitric Oxide testing (DEVICE).
Who is sponsoring clinical trial NCT05889013?
This trial is sponsored by Connecticut Children's Medical Center, which has 55 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT05889013 being conducted?
This trial has 1 study location across Connecticut. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Primary Ciliary Dyskinesia
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
-
Examining Bronchial Hyperresponsiveness in Primary Ciliary Dyskinesia
RECRUITING · NA
-
Use of Nasal Nitric Oxide Testing in Improving Primary Ciliary Dyskinesia Clinical Care
RECRUITING
-
Utility of PCD Diagnostics to Improve Clinical Care
RECRUITING · NA
-
A Longitudinal, Observational Study of Primary Ciliary Dyskinesia in Adults
ACTIVE NOT RECRUITING
-
A Study Providing Genetic Testing to Find Those Who May Have Primary Ciliary Dyskinesia for Potential Clinical Trials
ACTIVE NOT RECRUITING
-
Functional Studies of Novel Genes Mutated in Primary Ciliary Dyskinesia II: Genotype to Phenotype
COMPLETED · Early Phase 1
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT00200889 · 50 participants · Early Phase 1
Mapping Auricular Vagus Nerve Circuitry
- NCT00409435 · 50 participants · Phase 2
A Study of Pyridostigmine in Postural Tachycardia Syndrome
- NCT01202305 · 50 participants
The Use of Lymph Node Biopsies to Support HIV Pathogenesis Studies
- NCT01225913 · 50 participants · Phase 4
Mechanism(s) of Airflow Limitation During Exacerbation of Asthma
Similar registry start date
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia
- NCT07125183 · started 2026-12 · Phase 2
Study on Efficacy and Tolerability of Weekly Doxorubicin in Elderly Patients With Advanced or Metastatic Leiomyosarcoma
- NCT07292298 · started 2026-11 · Phase 2
Phase 2 Single-Arm Rectal Cancer Brachytherapy for Patients With Low-Lying Residual Adenocarcinoma After Total Neoadjuvant Therapy to Improve Organ Preservation Rates
- NCT04263285 · started 2026-10 · NA
Treatment of Depression Post-SCI